Advertisement

Loud Messengers — P Values and Effect Size

  • Lemuel A. Moyé

Abstract

Part of the application process for medical school admissions includes an interview with several faculty at the institution. While visiting one medical school that was considering me as a candidate, I was interviewed by a basic scientist— a neurophysiologist. During our conversation, the topic eventually turned to research. The interviewer finally commented that he was lamenting over a failed manuscript submission. Indulging my request for additional information, he related that his manuscript had been rejected by a prestigious journal, apparently for lack of statistical significance. Since I had some exposure to p values, we discussed their meaning and nonmeaning, jointly groping toward some inner truth, and finally realized together that “statistical significance” does not go hand in hand with clinical significance. We together broke some of the bonds with which p values had tied us so tightly. The purpose of this chapter is to break some more.

Keywords

High Blood Pressure Attributable Risk Primary Pulmonary Hypertension Expert Testimony Hazardous Drinking 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Noremberg, D., LRC, (1996) Letter to the Editor. JAMA 252: 2545.Google Scholar
  2. 2.
    Abenhaim, L., Moride, Y., and Brenot, F., (1996) “Appetite-suppressant drugs and the risk of primary pulmonary hypertension,” International Pulmonary Hypertension Study Groups [see comments], N Engl J Med 335: 609–616.PubMedCrossRefGoogle Scholar
  3. 3.
    Ouellet, B.L., Romeder, J.M. and Lance, J.M., (1979b) “Premature mortality attributable to smoking and hazardous drinking in Canada,” Am. J. Epidemiology 109: 451–463.Google Scholar
  4. 4.
    Thompson, W.D., (1987) “Statistical criteria in the interpretation of epidemiologic data (Different views),” American Journal of Public Health 77: 191–194.PubMedCrossRefGoogle Scholar
  5. 5.
    Poole, C., (1987) “Beyond the confidence interval,” American Journal of Public Health 77: 195–199.PubMedCrossRefGoogle Scholar
  6. 6.
    Times Newspaper Ltd., The Sunday Times of London, (1979) “Suffer the Children: The Story of Thalidomide.Google Scholar
  7. 7.
    Lenz, W., (1962) “Thalidomide and Congenital Abnormalities,” (Letter to the Editor) Lancet 1:45.Google Scholar
  8. 8.
    Clark, C., (1997) Radium Girls: Women and Industrial Health Reform, 1910–1935, University of North Carolina Press, Chapel Hill, NC.Google Scholar
  9. 9.
    Sacks, F.M., Pfeffer, M.A., and Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M.O., Wun, C.C., Davis, B.R., Braunwald, E. for the Cholesterol and recurrent Events Trial Investigators, (1996) “The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels,” N Engl J Med 335: 1001–1009.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Lemuel A. Moyé
    • 1
  1. 1.School of Public HealthUniversity of TexasHoustonUSA

Personalised recommendations